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Diabetes nephropathy is now the major cause of end-stage kidney disease globally in both developed and under progressed countries (1). It is the main diagnosis 
causing kidney insufficiency in 20–40% of people beginning 
treatment for end-stage renal disease global (1). Interstitial, 
vascular and glomerular injuries have been discovered the 
principal characters of diabetic renal disease (2). It is well 
found that, apoptosis linked to the development of diabetic 
nephropathy (2,3). In fact, high glucose augmented apoptosis, 
a form of programmed cell death presented by cell shrinkage, 
chromatin condensation and DNA fragmentation, in variety 
of cell types, especially kidney proximal tubular epithelial 
cells (2–4). Furthermore, diabetic kidneys are mostly prone 
to acute tubular damage in various clinical conditions, such 
as dehydration or post renal obstruction (2–5). It is also well 
defined that, hyperglycemia, by itself, is an independent risk 
factor for acute renal tubular injury under these situations. 
High blood glucose activates the generation of free radicals 
and oxidative stress in renal tubular cells. Reactive oxygen 
species (ROS) are believed to be principal mediators for several 
biologic responses, containing proliferation, extracellular 
matrix deposition and apoptosis (2–5). Actually, besides of 
apoptosis of proximal tubular epithelial cells by hyperglycemia, 
other cell types including endothelial cells and podocytes will 
also be affected by hyperglycemia (2–5). Thus, one of beneficial 
treatments in the diabetic nephropathy is using medications for 
inhibiting or reducing apoptosis to keep kidney tubular cells 
and podocytes as well. Metformin, an oral anti-diabetic drug in 
the biguanide class is a commonly prescribed drug to treat high 
blood glucose in patients with type 2 diabetes mellitus (T2DM) 
(6). Recent studies have documented that metformin possesses 
antioxidant properties, too. Reduction of apoptosis, induced by 
oxidative stress, in endothelial cells and inhibition of vascular 
dysfunction was also found during metformin treatment (6,7). 
The beneficial action of this drug is through activation of 
adenosine monophosphate-activated protein kinase (AMPK). 
This enzyme plays an important role in protecting cellular 
functions under energy-restricted conditions. Various studies, 
confirm that AMPK activation by metformin is secondary to its 
effect on the mitochondria as the primary target of this agent. 
There is some proof that the beneficial impact of metformin 
might be due to its mild inhibition of the mitochondrial 
respiratory chain, while the critical role of mitochondria 
in cell death is of significance importance and saving the 
mitochondria has become a pro-survival cell strategy (6–8). 
It is possible that the role of mitochondria in programmed 
cell death is associated with the release of apoptotic signaling 
molecules. ROS production by mitochondria may also lead 
significantly to cell injury. Previously, Morales et al. found 
that gentamicin-induced kidney tubular damage is attenuated 
by metformin (9). It is evident that, ROS play a key role in the 
toxicity of gentamicin, ensuing in acute renal damage, and 
gentamicin is a mitochondrial toxin that can imply its toxic 
properties when excreted by the kidney. Mitochondrial toxicity 
can also be mediated by ROS as mentioned above too (7–9). 
ROS is normally produced at low levels by mitochondria, 
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It is acceptable to interpret that metformin has three different responsibilities including: blood glucose 
regulatory effect, renal tubular cell protection by acting as an effective antioxidant and finally protective 
effect on diabetic nephropathy through saving the podocytes. Hence, diabetic patients may benefit from 
all of these three distinct ameliorative effects.  
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conversely under pathological conditions the intracellular and 
intra mitochondrial ROS content may be increased. When in 
certain situations, intracellular ROS content reaches to a toxic 
level, results in oxidative damage to the mitochondria, causing 
cell death and malfunctioning of the organ (7–9). To consider 
the potential kidney protective properties of metformin against 
gentamicin-induced kidney injury and also finding out whether 
postpone treatment with metformin in acute renal damage 
exerts parallel benefits on gentamicin kidney toxicity in rats, 
we conducted a study on male Wistar rats.  
In this study, metformin protected and also improved 
gentamicin-induced acute kidney damage, thus, this agent 
might be applicable for protection of renal tubular cells (10). 
Likewise, Denamur et al. (11)  observed that co-administration 
of metformin and gentamicin for 13 days effectively reversed 
gentamicin-induced renal damage. Thus, these findings 
provide further proof for the attribution of metformin in its 
renal protective effectiveness beyond its well-known blood 
sugar regulatory action (6–10). Accordingly, Kim et al. 
conducted a study using metformin for diabetic rats. They 
found the repair of podocytes by metformin in diabetic rats. 
They proposed that diabetes-induced podocyte loss in diabetic 
kidney disease could be reduced by metformin (12). Kim 
et al, also observed that the phosphorylation of AMPK was 
decreased in the kidney of diabetic rats, and metformin could 
return its alteration. Therefore, metformin might exert some 
of its effects by correction of kidney oxidative stress (12). Thus 
one might suggest metformin to inhibit the advanced glycation 
end-products and improve the free-radical defense system, 
hence, preventing the diabetic renal injury. 
It is well known that the damage to the podocytes lead to 
the occurrence of proteinuria (11,12). Therefore, the loss of 
glomerular podocytes precedes and predicts the onset of diabetic 
kidney disease and may be an early pathological presentation 
of diabetic nephropathy. Metformin significantly decreased 
albuminuria in patients with T2DM (3–7). Previous studies 
have also shown the favorable effects of metformin on reduction 
of macrovascular morbidity and mortality, suggesting anti-
atherogenic, antioxidant and anti-inflammatory effects (3–7). 
Additionally, metformin significantly decreased albuminuria 
in patients with T2DM, too (3–9). Therefore, it is acceptable 
to interpret that metformin has three different responsibilities, 
including: blood glucose regulatory effect, renal tubular cell 
protection by acting as an effective antioxidant and finally 
protective effect on diabetic nephropathy through saving the 
podocytes. Hence, diabetic patients may benefit from all of 
these three distinct ameliorative effects. 
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